AELIS FARMA SAS (AELIS.PA) Stock Price, Forecast & Analysis
Europe - EPA:AELIS - FR0014007ZB4 - Common Stock
AELIS.PA Key Statistics, Chart & Performance
The current stock price of AELIS.PA is 1.125 EUR. In the past month the price decreased by -3.02%. In the past year, price decreased by -60.94%.
AELIS.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 74.11 | 49.28B | ||
| 1AE.DE | ARGENX SE | 74.35 | 49.44B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.32B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.41B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.96B | ||
| GLPG.AS | GALAPAGOS NV | 23.7 | 1.75B | ||
| 5CV.DE | CUREVAC NV | 5.19 | 1.02B | ||
| NANO.PA | NANOBIOTIX | N/A | 867.88M | ||
| PHIL.MI | PHILOGEN SPA | 20.7 | 690.06M | ||
| IVA.PA | INVENTIVA SA | N/A | 511.97M | ||
| ALCLS.PA | CELLECTIS | N/A | 431.40M | ||
| FYB.DE | FORMYCON AG | N/A | 410.83M |
Related stock screener links
About AELIS.PA
Company Profile
Aelis Farma SA is a biopharmaceutical company. The company is headquartered in Bordeaux, Nouvelle-Aquitaine and currently employs 26 full-time employees. The company went IPO on 2022-02-18. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.
Company Info
AELIS FARMA SAS
Neurocentre Francois Magendie 146 Rue Leo, Saignat
Bordeaux NOUVELLE-AQUITAINE FR
Employees: 28
Phone: 33557573770
AELIS FARMA SAS / AELIS.PA FAQ
What does AELIS do?
Aelis Farma SA is a biopharmaceutical company. The company is headquartered in Bordeaux, Nouvelle-Aquitaine and currently employs 26 full-time employees. The company went IPO on 2022-02-18. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.
What is the current price of AELIS stock?
The current stock price of AELIS.PA is 1.125 EUR. The price decreased by -1.32% in the last trading session.
Does AELIS FARMA SAS pay dividends?
AELIS.PA does not pay a dividend.
How is the ChartMill rating for AELIS FARMA SAS?
AELIS.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists AELIS stock?
AELIS.PA stock is listed on the Euronext Paris exchange.
What is the expected growth for AELIS stock?
The Revenue of AELIS FARMA SAS (AELIS.PA) is expected to decline by -52.86% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
AELIS.PA Technical Analysis
AELIS.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AELIS.PA. AELIS.PA may be in some trouble as it scores bad on both profitability and health.
AELIS.PA Financial Highlights
Over the last trailing twelve months AELIS.PA reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS decreased by -13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.61% | ||
| ROE | -134.05% | ||
| Debt/Equity | 0.74 |
AELIS.PA Forecast & Estimates
9 analysts have analysed AELIS.PA and the average price target is 11.22 EUR. This implies a price increase of 897.33% is expected in the next year compared to the current price of 1.125.
For the next year, analysts expect an EPS growth of -131.58% and a revenue growth -52.86% for AELIS.PA